Biomarkers for prediction of skeletal disease progression in mucopolysaccharidosis type I
Abstract Background Orthopedic disease progresses in mucopolysaccharidosis type I (MPS I), even with approved therapies and remains a major factor in persistent suffering and disability. Novel therapies and accurate predictors of response are needed. The primary objective of this study was to identi...
Main Authors: | Troy C. Lund, Terence M. Doherty, Julie B. Eisengart, Rebecca L. Freese, Kyle D. Rudser, Ellen B. Fung, Bradley S. Miller, Klane K. White, Paul J. Orchard, Chester B. Whitley, Lynda E. Polgreen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-03-01
|
Series: | JIMD Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/jmd2.12190 |
Similar Items
-
Elements of lentiviral vector design toward gene therapy for treating mucopolysaccharidosis I
by: Li Ou, et al.
Published: (2016-09-01) -
Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement
by: Christiane S. Hampe, et al.
Published: (2021-01-01) -
Mucopolysaccharidosis: A broad review
by: Ritu Nagpal, et al.
Published: (2022-01-01) -
Mucopolysaccharidosis Type I
by: Francyne Kubaski, et al.
Published: (2020-03-01) -
An online survey on burden of illness among families with post-stem cell transplant mucopolysaccharidosis type I children in the United States
by: Therese Conner, et al.
Published: (2019-02-01)